DexCom DXCM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 237.3%-10.4pp | 247.7%-7.7pp | 255.4%-7.8pp | 263.2%-11.3pp | |
| Operating margin | 68%+2.8pp | 65.2%+6.7pp | 58.5%+16.5pp | 42%-16.0pp | |
| Net margin | 60.1%-5.2pp | 65.3%+18.4pp | 46.9%+7.2pp | 39.7%-54.1pp | |
| Returns | |||||
| Return on equity | 111.7%-6.0pp | 117.6%+43.8pp | 73.8%+21.0pp | 52.9%-72.6pp | |
| Return on invested capital | 146.6%+10.4pp | 136.2%+49.4pp | 86.8%+5.0pp | 81.8%-50.9pp | |
| Efficiency | |||||
| Asset turnover | 2.6×+0.2× | 2.5×+0.1× | 2.3×+0.1× | 2.2×0.0× | |
| Liquidity | |||||
| Current ratio | 6.5×-3.2× | 9.6×-0.4× | 10.1×-5.7× | 15.8×-5.8× | |
| Leverage | |||||
| Debt-to-equity | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Net debt / EBITDA | -4.3×-1.5× | -2.8×+0.9× | -3.7×+1.3× | -5.1×+3.8× | |
| Per Share | |||||
| Book value per share | $25.33+19.8% | $21.15+3.8% | $20.38+3.3% | $19.73-39.5% | |
| Valuation | |||||
| Market capitalization | $113.39B-27.2% | $155.8B-12.6% | $178.26B+15.6% | $154.19B-14.9% | |
| Price / earnings | 177.7×-65.7× | 243.4×-233× | 476.3×-91.4× | 567.7×+123× | |
| Price / sales | 25.8×-14.0× | 39.9×-14.3× | 54.1×-2.4× | 56.6×-23.8× | |
| Price / book | 44.3×-26.1× | 70.3×-12.3× | 82.7×+9.2× | 73.4×-15.9× | |
| EV / EBITDA | 112.1×-68.0× | 180.2×-92.4× | 272.5×-86.8× | 359.3×-75.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are DexCom's profit margins?
- DexCom (DXCM) runs a 61.5% gross margin and a 21.4% operating margin, with a 19.3% net margin.
- Where do DexCom's ratios come from?
- Every ratio is computed from DexCom's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
